These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 25994537)

  • 21. Stromal expression of SPARC in pancreatic adenocarcinoma.
    Neuzillet C; Tijeras-Raballand A; Cros J; Faivre S; Hammel P; Raymond E
    Cancer Metastasis Rev; 2013 Dec; 32(3-4):585-602. PubMed ID: 23690170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Current aspects of chemotherapy of metastatic pancreatic and biliary tract carcinomas].
    Bokemeyer C; Kollmannsberger C; Oettle H; Kanz L
    Praxis (Bern 1994); 2000 Sep; 89(39):1545-52. PubMed ID: 11068508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular-based and alternative therapies for pancreatic cancer: looking "out of the box".
    Tholey R; Sawicki JA; Brody JR
    Cancer J; 2012; 18(6):665-73. PubMed ID: 23187855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrin-based therapy of pancreatic adenocarcinoma: current status and future perspectives.
    Oron Y
    Minerva Gastroenterol Dietol; 2015 Jun; 61(2):71-86. PubMed ID: 25610998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer.
    Ghosn M; Farhat F; Kattan J; Younes F; Moukadem W; Nasr F; Chahine G
    Am J Clin Oncol; 2007 Feb; 30(1):15-20. PubMed ID: 17278889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted therapies in pancreatic cancer: Promises and failures.
    Barati Bagherabad M; Afzaljavan F; ShahidSales S; Hassanian SM; Avan A
    J Cell Biochem; 2019 Mar; 120(3):2726-2741. PubMed ID: 28703890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current status in chemotherapy for advanced pancreatic adenocarcinoma.
    Cao H; LE D; Yang LX
    Anticancer Res; 2013 May; 33(5):1785-91. PubMed ID: 23645722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Horizons in the Treatment of Metastatic Pancreatic Cancer: A Review of the Key Biology Features and the Most Recent Advances to Treat Metastatic Pancreatic Cancer.
    Verdaguer H; Arroyo A; Macarulla T
    Target Oncol; 2018 Dec; 13(6):691-704. PubMed ID: 30470972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies.
    Teague A; Lim KH; Wang-Gillam A
    Ther Adv Med Oncol; 2015 Mar; 7(2):68-84. PubMed ID: 25755680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pancreatic Neoplasms and Autophagy.
    Barton LA; Ren J
    Curr Drug Targets; 2018; 19(9):1018-1023. PubMed ID: 27358060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA).
    Uccello M; Moschetta M; Mak G; Alam T; Henriquez CM; Arkenau HT
    Curr Oncol; 2018 Feb; 25(1):e90-e94. PubMed ID: 29507500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma.
    Ramfidis VS; Syrigos KN; Saif MW
    JOP; 2013 Jul; 14(4):344-6. PubMed ID: 23846924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
    Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
    Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Taxanes: impact on pancreatic cancer.
    Chiorean EG; Von Hoff DD
    Anticancer Drugs; 2014 May; 25(5):584-92. PubMed ID: 24463484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies.
    Matera R; Saif MW
    Expert Opin Emerg Drugs; 2017 Sep; 22(3):223-233. PubMed ID: 28783977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemoresistance in pancreatic cancer: Emerging concepts.
    Gnanamony M; Gondi CS
    Oncol Lett; 2017 Apr; 13(4):2507-2513. PubMed ID: 28454427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current status and future prospect of pharmacotherapy for pancreatic cancer].
    Fang Y; Lai MR; Ge YQ; Zhang GJ; Cheng RB
    Zhongguo Zhong Yao Za Zhi; 2019 Apr; 44(8):1509-1516. PubMed ID: 31090312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aggressive and Drug-resistant Pancreatic Cancer: Challenges and Novel Treatment Approaches.
    Abbas M; Alqahtani MS; Alshahrani MY; Alabdullh K
    Discov Med; 2022; 34(173):158-164. PubMed ID: 36482765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multidisciplinary management of pancreatic cancer.
    Tempero MA
    J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):700-2. PubMed ID: 25995435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.